Search results for " lymphoma"

showing 10 items of 448 documents

Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management.

2013

Endoscopic ultrasonography (EUS) has recently gained a pivotal role in the management of gastric lymphomas, especially in the diagnostic workup. Its accuracy and reliability have overcome those of other imaging techniques, such that it represents an invaluable tool for the management of gastric lymphomas. Although this technique is operator dependent, its application in large series has proved its reliability. Thus, it has generally been considered a useful tool for providing information crucial in deciding the treatment program, especially for mucosa-associated lymphoid tissue (MALT) lymphomas, for which EUS can provide an accurate evaluation of disease extension and treatment response pro…

Cancer Researchmedicine.medical_specialtyTreatment responseDecision MakingEndoscopic ultrasonographyDiseaseGastroenterologyEndosonographyStomach NeoplasmsSubmucosaInternal medicinemedicineHumansNeoplasm Stagingbiologybusiness.industryGastric lymphomaStomachLymphoma Non-HodgkinDisease ManagementHematologyHelicobacter pylorimedicine.diseasebiology.organism_classificationPrognosisdigestive system diseasesPatient managementmedicine.anatomical_structureTreatment OutcomeOncologyRadiologybusinessClinical lymphoma, myelomaleukemia
researchProduct

Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up

2011

The reliability of endoscopic ultrasonography (EUS) in follow-up management of gastric lymphomas has not been clearly validated. We conducted a retrospective analysis on 23 patients, 12 affected by mucosa-associated lymphoid tissue (MALT) lymphoma, eight by diffuse large B-cell lymphoma, and three by high-grade lymphoma with low-grade component, all treated with a stomach-conservative approach. One hundred and twenty matched evaluations with both EUS and endoscopy with biopsy (E-Bx) were performed, according to validated guidelines and clinical judgment. At a median follow-up of 87 months ranged between 9.5 and 166 months, the analysis of progression-free survival and disease-free survival …

Cancer Researchmedicine.medical_specialtymedicine.diagnostic_testbusiness.industryMALT lymphomaRetrospective cohort studyHematologyGeneral Medicinemedicine.diseasedigestive system diseasesLymphomaSurgeryEndoscopyLymphatic systemOncologyimmune system diseaseshemic and lymphatic diseasesBiopsymedicineRadiologyYoung adultbusinessSurvival rateHematological Oncology
researchProduct

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma

2015

Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigated expression and function of IL-17A/IL-17AR in the microenvironments of 44 B cell non-Hodgkin lymphomas (B-NHL) of GC origin (15 follicular lymphomas, 17 diffuse large B cells lymphomas and 12 Burkitt lymphomas) and 12 human tonsil GC. Furthermore, we investigated the role of IL-17A in two in vivo models of GC B cell lymphoma, generated by s.c. injection of SU-DHL-4 and OCI-Ly8…

Cell typeImmunologySettore MED/08 - Anatomia PatologicaangiogenesisB non-Hodgkin lymphomahemic and lymphatic diseasesmedicineIL-17AImmunology and Allergytumor immunologyCXCL13B-cell lymphomaangiogenesis; B non-Hodgkin lymphoma; GC B cells; IL-17A; IL-17A receptor; tumor immunology; Immunology and Allergy; Oncology; ImmunologyB cellOriginal ResearchSevere combined immunodeficiencybusiness.industryIL-17A receptorGerminal centerInterleukinangiogenesimedicine.diseaseMolecular biologyGC B cellmedicine.anatomical_structureOncologyCell cultureImmunologyGC B cellsbusiness
researchProduct

Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types

2020

A new class of pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles was synthesized for the treatment of hyperproliferative pathologies, including neoplasms. The new compounds were screened in the 60 human cancer cell lines of the NCI drug screen and showed potent activity with GI50 values reaching the nanomolar level, with mean graph midpoints of 0.08-0.41 μM. All compounds were further tested on six lymphoma cell lines, and eight showed potent growth inhibitory effects with IC50 values lower than 500 nM. Mechanism of action studies showed the ability of the new [1,2]oxazoles to arrest cells in the G2/M phase in a concentration dependent manner and to induce apoptosis through the mitochondrial…

CellsMitosisAntineoplastic AgentsApoptosisAntimitotic AgentsDrug Screening Assays[12]oxazoles antimitotic agents lymphoma tubulin polymerization inhibitorsDose-Response RelationshipStructure-Activity Relationshipchemistry.chemical_compoundModelsDrug DiscoverymedicineHumansStructure–activity relationshipColchicineOxazolesAntimitotic Agents; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cells Cultured; Dose-Response Relationship Drug; Drug Screening Assays Antitumor; G2 Phase Cell Cycle Checkpoints; HeLa Cells; Humans; Mitosis; Models Molecular; Molecular Structure; Oxazoles; Structure-Activity RelationshipCell Proliferationchemistry.chemical_classificationReactive oxygen speciesCulturedMolecular StructureChemistryMolecularDepolarizationAntitumorMolecular biologyG2 Phase Cell Cycle CheckpointsMechanism of actionApoptosisCell cultureMolecular MedicineAntimitotic AgentDrugmedicine.symptomHeLa Cells
researchProduct

Bone damage after chemotherapy for lymphoma: a real-world experience

2021

AbstractBackgroundDespite recent improvements in survival due to advances in treatment, the quality of life of patients with lymphoma may be compromised by the long-term complications of chemotherapy and steroid therapy. Among these, a potentially relevant problem is bone loss and the development of fragility fractures.AimTo provide further evidence of clinical or subclinical skeletal complications in correlation with biological variables and markers of bone disease in patients with complete response to therapy.MethodA cross-sectional observational study was conducted on subjects diagnosed with lymphoma with subsequent antineoplastic treatment, disease status after therapy defined as comple…

Chemotherapy Osteoporosis Lymphoma Steroids Bone losses OsteoclasticLymphomaBone lossesResearchOsteoclasticDiseases of the musculoskeletal systemVitamin D DeficiencyCross-Sectional StudiesRC925-935RheumatologyBone DensityQuality of LifeBone losses; Chemotherapy; Lymphoma; Osteoclastic; Osteoporosis; Steroids; Aged; Bone Density; Cross-Sectional Studies; Humans; Quality of Life; Lymphoma; Osteoporosis; Vitamin D DeficiencyHumansOsteoporosisChemotherapySteroidsOrthopedics and Sports MedicineAgedBMC Musculoskeletal Disorders
researchProduct

Pediatric Anaplastic Large Cell Lymphoma with Concomitant Involvement of Spine and Central Nervous System: A Case Report and Review of Literature

2021

Anaplastic large cell lymphoma (ALCL) is a histological subtype of non-Hodgkin lymphoma, largely characterized by anaplastic lymphoma kinase (ALK) positivity, resulting from the chromosomal translocation t(2;5). We report a pediatric case of ALK-positive ALCL with primary concomitant involvement of bone and central nervous system (CNS); thereafter, a literature review about pediatric primary bone and primary CNS ALCL was conducted. According to the analyzed data, our case is unique because it is characterized by the contemporary involvement of the spine and CNS. During and after chemotherapy, our patient was monitored by detecting minimal residual disease (MRD) through the analysis of fusio…

ChemotherapyPathologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentRcentral nervous systemmedicine.diseaseboneMinimal residual diseaseLymphomamedicine.anatomical_structureFusion transcriptanaplastic large cell lymphomahemic and lymphatic diseasesConcomitantminimal residual diseasemedicineMedicineAnaplastic lymphoma kinaseBone marrowbusinessAnaplastic large-cell lymphomaHemato
researchProduct

Whole-body magnetic resonance for staging and response assessment of lymphoma in a pregnant woman treated with antenatal chemotherapy

2017

A 32-year-old pregnant female presented with bilateral supraclavicular swelling, diffuse itching and right shoulder pain. After lymph nodal biopsy, a diagnosis of nodular sclerosis Hodgkin's lymphoma was obtained. A multidisciplinary team decided to start chemotherapy before the delivery, and whole-body MRI was used to stage the disease and evaluate the response after antenatal chemotherapy. This case shows that whole-body MRI is an attractive procedure that avoids radiation exposure and contrast administration, and enables staging and follow-up of a pregnant patient without risk to the fetus.

Chemotherapymedicine.medical_specialtyFetusmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentMagnetic resonance imagingCase ReportGeneral Medicinemedicine.disease030218 nuclear medicine & medical imagingSurgeryLymphoma03 medical and health sciencesMagnetic resonance imaging . Whole body imaging . Lymphoma . Pregnancy0302 clinical medicineNodular sclerosis030220 oncology & carcinogenesisBiopsymedicineItchingmedicine.symptomStage (cooking)businessBJR Case Reports
researchProduct

Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32

2010

To identify susceptibility loci for non-Hodgkin lymphoma subtypes, we conducted a three-stage genome-wide association study. We identified two variants associated with follicular lymphoma at 6p21.32 (rs10484561, combined P = 1.12 × 10-29 and rs7755224, combined P = 2.00 × 10-19; r2 = 1.0), supporting the idea that major histocompatibility complex genetic variation influences follicular lymphoma susceptibility. We also found confirmatory evidence of a previously reported association between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 × 10-9). © 2010 Nature America, Inc. All rights reserved.

Chronic lymphocytic leukemiaFollicular lymphomaLocus (genetics)Genome-wide association studyHuman leukocyte antigenBiologyArticleMajor Histocompatibility Complex03 medical and health sciences0302 clinical medicinefollicular lymphomaRisk Factorshemic and lymphatic diseasesGeneticsmedicineHumansLymphoma Follicular030304 developmental biology0303 health sciencesLymphoma Non-HodgkinGenetic Variation16. Peace & justicemedicine.diseaseLeukemia Lymphocytic Chronic B-Cell3. Good healthLymphomaNon-Hodgkin's lymphomaLeukemia030220 oncology & carcinogenesisImmunologyDisease SusceptibilityGenome-Wide Association Study
researchProduct

A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome

2010

Richter syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma. Risk factors of CLL transformation to RS are only partly known. We explored the role of the host genetic background as a risk factor for RS occurrence. Forty-five single nucleotide polimorphisms (SNPs) known to be relevant for CLL prognosis were genotyped in a consecutive cohort of 331 CLL, of which 21 had transformed to RS. After correcting for multiple testing and adjusting for previously reported RS risk factors, the LRP4 rs2306029 TT variant genotype was the sole SNP independently associated with a higher risk of RS transformation (Hazard Ratio: 4·17; P = 0·001; q = 0·047).…

Chronic lymphocytic leukemiaSingle-nucleotide polymorphismAggressive lymphomaHematologyBiologymedicine.diseasehemic and lymphatic diseasesImmunologyGenotypemedicineSNPRisk factorGenotypingDiffuse large B-cell lymphomaBritish Journal of Haematology
researchProduct

Complement receptors on lymphocytes

1981

Complement component 5Cancer ResearchErythrocytesRosette FormationSheepComplement component 2CD46ChemistryComplement C3General MedicineComplement receptorImmune receptorBurkitt LymphomaComplement factor BCell LineReceptors ComplementClassical complement pathwayOncologyImmunologyAnimalsHumansLymphocytesCFHR5Journal of Cancer Research and Clinical Oncology
researchProduct